Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 270

1.

Tumour vaccine approaches for CNS malignancies: progress to date.

Ebben JD, Rocque BG, Kuo JS.

Drugs. 2009;69(3):241-9. doi: 10.2165/00003495-200969030-00001. Review.

PMID:
19275269
2.

Dendritic-cell- and peptide-based vaccination strategies for glioma.

Yamanaka R.

Neurosurg Rev. 2009 Jul;32(3):265-73; discussion 273. doi: 10.1007/s10143-009-0189-1. Epub 2009 Feb 13. Review.

PMID:
19214609
3.

T cell immunity in patients with malignant glioma: recent progress in dendritic cell-based immunotherapeutic approaches.

Akasaki Y, Black KL, Yu JS.

Front Biosci. 2005 Sep 1;10:2908-21. Review.

PMID:
15970545
4.

Peptide-based immunotherapeutic approaches to glioma: a review.

Yamanaka R, Itoh K.

Expert Opin Biol Ther. 2007 May;7(5):645-9. Review.

PMID:
17477802
5.

Progress in active-specific immunotherapy of brain malignancies.

Tjoa BA, Salgaller ML.

Expert Opin Investig Drugs. 2000 Sep;9(9):2093-101. Review.

PMID:
11060795
6.

Peptide vaccine.

Izumoto S.

Adv Exp Med Biol. 2012;746:166-77. doi: 10.1007/978-1-4614-3146-6_13. Review.

PMID:
22639167
7.

Immunotherapy of diffuse gliomas: biological background, current status and future developments.

Grauer OM, Wesseling P, Adema GJ.

Brain Pathol. 2009 Oct;19(4):674-93. doi: 10.1111/j.1750-3639.2009.00315.x. Review.

PMID:
19744040
8.

Novel immunotherapeutic approaches to glioma.

Yamanaka R.

Curr Opin Mol Ther. 2006 Feb;8(1):46-51. Review.

PMID:
16506525
9.

Cancer vaccines: an update.

Hipp JD, Hipp JA, Lyday BW, Minev BR.

In Vivo. 2000 Sep-Oct;14(5):571-85. Review.

PMID:
11125541
10.

[Peptide vaccination therapy for malignant glioma].

Yamanaka R, Itoh K.

Brain Nerve. 2007 Mar;59(3):251-61. Review. Japanese.

PMID:
17370651
11.

Cytokine gene therapy for malignant glioma.

Okada H, Pollack IF.

Expert Opin Biol Ther. 2004 Oct;4(10):1609-20. Review.

PMID:
15461572
12.

Glioma immunology and immunotherapy.

Parney IF, Hao C, Petruk KC.

Neurosurgery. 2000 Apr;46(4):778-91; discussion 791-2. Review.

PMID:
10764250
13.

Dendritic cell-based immunotherapy for malignant gliomas.

Akasaki Y, Black KL, Yu JS.

Expert Rev Neurother. 2005 Jul;5(4):497-508. Review.

PMID:
16026233
14.

Cell- and peptide-based immunotherapeutic approaches for glioma.

Yamanaka R.

Trends Mol Med. 2008 May;14(5):228-35. doi: 10.1016/j.molmed.2008.03.003. Epub 2008 Apr 9. Review.

PMID:
18403264
15.

Exploitation of immune mechanisms in the treatment of central nervous system cancer.

Pollack IF, Okada H, Chambers WH.

Semin Pediatr Neurol. 2000 Jun;7(2):131-43. Review.

PMID:
10914414
16.

Vaccine strategies to treat lymphoproliferative disorders.

Radford KJ, Vari F, Hart DN.

Pathology. 2005 Dec;37(6):534-50. Review.

PMID:
16373232
17.

Dendritic cell vaccines and immunity in glioma patients.

Wheeler CJ, Black KL.

Front Biosci. 2005 Sep 1;10:2861-81. Review.

PMID:
15970541
18.

Dendritic cell therapy of high-grade gliomas.

Van Gool S, Maes W, Ardon H, Verschuere T, Van Cauter S, De Vleeschouwer S.

Brain Pathol. 2009 Oct;19(4):694-712. doi: 10.1111/j.1750-3639.2009.00316.x. Review.

PMID:
19744041
19.

Mahaley Clinical Research Award: chemosensitization of glioma through dendritic cell vaccination.

Yu JS, Luptrawan A, Black KL, Liu G.

Clin Neurosurg. 2006;53:345-51. Review.

PMID:
17380773
20.

Recent advances in heat shock protein-based cancer vaccines.

Wang HH, Mao CY, Teng LS, Cao J.

Hepatobiliary Pancreat Dis Int. 2006 Feb;5(1):22-7. Review.

PMID:
16481277

Supplemental Content

Support Center